Argent BioPharma (ASX: RGT) has confirmed that pharmaceutical manufacturer ECCPharm will take on full production and release responsibilities for Argent’s emerging cannabinoid therapies under a strategic partnership between the two companies.
The agreement will ensure the CannEpil and CogniCann treatments are available under early patient access programs in key European countries including Ireland, the UK and Germany.
Argent will retain ownership of all current and future research and development, as well as intellectual property rights, under the partnership.
A technology transfer will relocate the products’ official manufacturing base from Argent’s European facilities to ECCPharm’s state-of-the-art facility in North Macedonia at Argent’s expense.
The move aims to enhance production efficiency, ensure regulatory compliance and support scalable manufacturing to meet growing global patient demand for high-quality, medical cannabis-based pharmaceuticals.
The transfer process will commence immediately, with manufacturing at ECCPharm’s North Macedonian facility expected to begin in the coming months.
The strategic partnership will allow Argent to focus resources on the clinical development and medical advancement of new products.
It will also deliver operational cost reductions for Argent and minimise monthly cash flow burn from running its own manufacturing facilities within Europe.
“By leveraging ECCPharm’s manufacturing expertise, we will secure a scalable, cost-effective production platform for CannEpil and CogniCann,” Argent chief executive officer Roby Zomer said.
“It will allow us to concentrate on our core mission of advancing clinical development and expanding regulatory approvals worldwide.”
CannEpil is a clinically supported treatment for patients with refractory epilepsy who have not benefited from traditional anti-epileptic drugs.
After conducting human trials in Australia and gathering real-world data over the years, Argent expects CannEpil to be available under early patient access programs in key European markets.
CogniCann is an investigational therapy targeting various types of dementia including Alzheimer’s and Parkinson’s disease.
Early clinical trial results in Australia have indicated that use of the drug could deliver improvements in cognitive function, behaviour and overall patient well-being.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.